Koenigsmann, M., Casper, J., Kahl, C., Basara, N., Sayer, H. G., Behre, G., Theurich, S., Christopeit, M., Mohren, M., Reichle, A., Metzner, B., Ganser, A., Stadler, M., Uharek, L., Balleisen, L., Hinke, A., Hinke, R. and Niederwieser, D. (2014). Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. Bone Marrow Transplant., 49 (3). S. 410 - 416. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Full text not available from this repository.

Abstract

Since the outcome of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) is highly variable, a risk-adapted treatment approach was evaluated. After two cycles of DHAP, patients received high-dose treosulfan/etoposide/carboplatinum (TEC) and autologous stem cell rescue. After TEC, low-risk patients with late relapse (> 1 year after first CR who achieved CR after DHAP received no further treatment. Patients with late relapse who achieved CR or PR only after TEC underwent a second cycle of TEC. High-risk patients with early relapse/refractory disease received treosulfan/fludarabine followed by allogeneic transplantation. Rituximab was added in patients with B-cell lymphoma (86%). At entry, 36% of all 57 patients had refractory disease, 32% early and 32% late relapse. During DHAP treatment, progression occurred in 32% of patients. Of 33 patients who received TEC, 5 received second TEC and 15 allogeneic transplantation. Main toxicity after TEC was oral mucositis (CTC grades 3 and 4 in 50% and 13%, respectively). In total, 42% patients achieved CR. Median OS was 21.4 months for all patients and 32.6 for those who underwent allogeneic transplantation. International prognostic index (IPI) at study entry was highly discriminative at predicting OS (P < 0.0001). Risk-adapted, treosulfan-based therapy with auto -and allo-SCT is feasible. Long-term survival is possible with allogeneic transplantation.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Koenigsmann, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Casper, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kahl, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Basara, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sayer, H. G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Behre, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Theurich, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Christopeit, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mohren, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reichle, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Metzner, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ganser, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stadler, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Uharek, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Balleisen, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hinke, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hinke, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Niederwieser, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-444668
DOI: 10.1038/bmt.2013.199
Journal or Publication Title: Bone Marrow Transplant.
Volume: 49
Number: 3
Page Range: S. 410 - 416
Date: 2014
Publisher: NATURE PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 1476-5365
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; SALVAGE THERAPY; LYMPHOMA; BLOOD; RITUXIMAB; REGIMENS; GRADE; MALIGNANCIESMultiple languages
Biophysics; Oncology; Hematology; Immunology; TransplantationMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/44466

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item